Form 8-K - Current report:
SEC Accession No. 0001193125-24-090821
Filing Date
2024-04-09
Accepted
2024-04-09 16:14:01
Documents
15
Period of Report
2024-04-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816494d8k.htm   iXBRL 8-K 27319
2 EX-99.1 d816494dex991.htm EX-99.1 5602
6 GRAPHIC g816494g0409024325657.jpg GRAPHIC 3935
  Complete submission text file 0001193125-24-090821.txt   164549

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elvn-20240408.xsd EX-101.SCH 2886
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20240408_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20240408_pre.xml EX-101.PRE 11282
18 EXTRACTED XBRL INSTANCE DOCUMENT d816494d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 24832872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)